Jean Kagubare, deputy director for Health Systems Design, shares the importance of investing in primary health care (PHC) as part of the global response to COVID-19. By strengthening basic health…
CEO Mark Suzman reflects on the foundation’s unique position to respond to the COVID-19 crisis and shares an update on the foundation’s more than $250 million commitment to funding response…
Trevor Mundel, who leads the foundation’s efforts to develop high-impact interventions against the leading causes of death and disability in developing countries, discusses the first trials funded through the Therapeutics…
Monalisa Chatterji, a senior program officer for the Bill & Melinda Gates Foundation’s Discovery & Translational Sciences team, works on the discovery of novel candidate therapeutics.
Interview with Trevor Mundel on COVID-19. Mundel leads the foundation’s efforts to develop high-impact interventions against the leading causes of death and disability in developing countries.
We are joining forces with Wellcome and Mastercard to beef up our COVID-19 response—backed by $125 million in both new funding and money already earmarked to tackle this epidemic. The…
Interview with Ken Duncan on COVID-19 (novel coronavirus). Duncan leads drug discovery efforts for the Bill & Melinda Gates Foundation’s Discovery & Translational Sciences team.
Interview with Valerie Nkamgang Bemo on COVID-19. Bemo manages the Bill & Melinda Gates Foundation’s investments that support communities affected by natural disasters and complex emergencies.
In Burkina Faso, the seasonal “Harmattan” winds have traditionally been associated with deadly meningitis outbreaks. But the winds have changed. A historic partnership between Burkina Faso and Gavi, the Vaccine…
